India - UK Biosimilar Corridor: A Controlled Evidence Pathway
NHS England’s Commissioning Framework for Best Value Biological Medicines reports that the NHS spends approximately £1.4 billion on biological medicines due to lose patent protection between now and 2028, presenting an opportunity to secure up to £1 billion in savings through timely biosimilar uptake. It sets an ambition for 100% of new patients to be initiated on the best-value biological within three months of launch, where clinically appropriate, and at least 80% of existing patients to move within ten months. From 28 April 2026, the amended UK Clinical Trials Regulations make compliance with the ICH E6(R3) GCP principles a legal requirement for UK clinical trials of investigational medicinal products. The policy signal is clear. But UK authorisation, NHS use and uptake still depend on licensure, procurement, commissioning, clinical acceptance, prescriber judgement, patient suitability, and supply readiness. None of those steps are automatic.
A Cross-Border Pathway Built on Evidence Control
The India-UK biosimilar corridor describes the evidence and execution pathway between India’s biosimilar development framework, governed by CDSCO and the Department of Biotechnology, and the statutory, scientific, and governance requirements a biosimilar applicant must satisfy to obtain UK marketing authorisation through MHRA. It is not a formal regulatory route recognised by either authority. It is a development and submission strategy where evidence generated in India must be translated into a UK-compliant regulatory package. This matters because both systems use a totality-of-evidence approach but do not ask the same questions in the same way. The gap starts with the reference product, continues through CMC comparability, PK design, clinical justification, pharmacovigilance, and post-authorisation control, and ends with whether the sponsor’s documentation survives regulatory scrutiny. A dossier does not travel by geography. It travels by evidence quality.
What UK Regulatory Review Requires
MHRA expects the UK reference medicinal product to anchor the comparability exercise. A non-UK reference product requires justification and, where needed, robust analytical bridging to demonstrate representativeness of the UK product. Multiple reference product batches should support the quality target product profile. For some critical quality attributes, tens of batches over a suitable period would normally be expected unless an exception is justified.
The clinical comparability exercise should include a pivotal comparative pharmacokinetic trial. It is strongly recommended that the pivotal PK trial uses biosimilar product derived from the commercial manufacturing process and representative of the intended commercial quality profile. The trial must be designed and powered to demonstrate equivalence. An 80.00% to 125.00% interval is generally acceptable, but equivalence margins must be prespecified and justified in the protocol and/or statistical analysis plan. Safety and immunogenicity data should also be collected and presented during this trial.
MHRA does not request in vivo animal studies to demonstrate biosimilar comparability. If GLP toxicity studies were conducted for another regulatory authority, the reports must still be submitted. A comparative efficacy trial may not be necessary in most cases if a sound scientific rationale supports this approach, but the position is case-specific and must be justified in the submission. All in vitro pharmacology data belongs in CTD Module 3.
Where a UK clinical trial of an investigational medicinal product is required, the sponsor works through Combined Review via IRAS. Where the product is manufactured outside the UK, each manufacturing site requires an importer’s authorisation and a Qualified Person declaration confirming GMP compliance. Under the standard route, valid applications receive a combined MHRA and Research Ethics Committee decision within 30 calendar days of validation. If further information is requested, the applicant has 60 calendar days to respond; the final decision follows within 10 calendar days of a complete response. Registration must occur before the first participant gives consent. Where this is not possible, registration must be completed within 90 calendar days of the date of approval. Within 12 months of trial conclusion, the sponsor must publish a summary of results in the same public registry and offer an accessible summary to participants, unless a deferral or waiver applies. Failure to register or publish a summary of results, where no deferral or waiver applies, is an offence under the Regulations. A trial approval lapses if no participant has signed consent within two years of the date of approval, unless an extension is granted.
What India Requires
India regulates similar biologics through a combined statutory and guidance framework. The 2016 CDSCO-DBT Similar Biologics Guidelines sit under the Drugs and Cosmetics Act 1940, the Drugs and Cosmetics Rules 1945, and, where genetically engineered organisms or cells are involved, the 1989 Rules notified under the Environment (Protection) Act 1986. Current clinical trial and new drug requirements must also be read with the New Drugs and Clinical Trials Rules, 2019. CDSCO is responsible for clinical trial approval and permission for manufacture and marketing. DBT, through RCGM, oversees development and preclinical evaluation of recombinant DNA-derived products. CDSCO issued draft revised Similar Biologics Guidelines for stakeholder comment on 6 May 2025; these should be treated as draft until finalised.
Under the 2016 guidelines, the reference biologic must be approved in India or, where not marketed in India, licensed in an ICH country. Under the 2016 framework, comparative Phase III clinical data remains central. Clinical trials are required to demonstrate similarity in safety and efficacy, generally in not fewer than 100 evaluable patients in the test arm. A waiver of the comparative clinical safety and efficacy study is possible only where defined analytical, preclinical; PK/PD, safety, immunogenicity, and risk management conditions are fully met. The 2016 guidelines state explicitly that the confirmatory clinical safety and efficacy study cannot be waived for large molecular weight biologics such as monoclonal antibodies.
Post-approval obligations are material. Under the 2016 guideline, periodic safety update reports are submitted every six months for the first two years and annually for the subsequent two years. A Phase IV post-marketing study in more than 200 evaluable patients is generally expected, preferably completed within two years of marketing permission or manufacturing licence unless justified. Where pre-approval studies included more than 100 patients on the proposed similar biologic, the Phase IV population may be adjusted so that combined Phase III and Phase IV safety data cover at least 300 patients.
The Control Points That Decide the Pathway
A credible India-UK biosimilar programme needs control over:
- UK RMP and RP bridging strategy
- CMC comparability and commercial-process alignment
- PK design and equivalence margins
- Phase III and Phase IV evidence mapping
- pharmacovigilance and RMP alignment
- IMP importation, QP declaration and GMP documentation
- IRAS, REC and participant-facing documentation
- prospective TMF control and inspection readiness
- sponsor oversight of CROs, vendors, laboratories and trial systems
Abiogenesis: Supporting Sponsors from Evidence Strategy to Delivery Control
Abiogenesis supports biosimilar sponsors where India-UK development requires regulatory translation and delivery control. This includes pathway planning, submission-readiness review, MHRA scientific advice preparation where appropriate, IRAS and Combined Review support for UK CTIMPs, ICH E6(R3)-aligned operational planning, sponsor-site coordination, participant-facing document support, pharmacovigilance planning, prospective TMF management and cross-border delivery oversight.
Abiogenesis supports sponsor preparedness and operational control. Sponsor accountability remains unchanged. MHRA, REC, HRA, NICE, NHS bodies, CDSCO and other competent authorities make independent regulatory, ethics, transparency, recommendation, commissioning, adoption and authorisation decisions.
The Strategic Position
The India-UK biosimilar pathway only holds value when UK requirements are planned early, not added at submission stage. The reference product strategy must be defensible. The CMC, PK, clinical and safety packages must support the biosimilar claim. Pharmacovigilance must map Indian commitments against UK obligations. The TMF must show sponsor oversight, delegation control and decision traceability.
This is a controlled evidence pathway, not a geography-led route. Sponsors who translate Indian evidence into a UK-ready quality, clinical, safety and governance record enter review with stronger discipline. Sponsors should not assume an Indian dossier satisfies UK scrutiny without UK-specific justification. Evidence control, documentation discipline, governance, safety systems, site readiness and delivery execution decide the pathway.